CJC-1295 Liver Function Impact: What the Clinical Data Actually Show

How CJC-1295 Interacts With the Liver

CJC-1295 does not act directly on hepatocytes. Instead, it binds pituitary GHRH receptors, triggers pulsatile GH release, and that GH then travels to the liver where it binds GH receptors on hepatocytes to stimulate IGF-1 synthesis. The liver is central to CJC-1295's mechanism, not as a toxicity target but as the primary effector organ for the peptide's downstream anabolic signal.

Understanding this distinction matters clinically. When a prescriber orders a liver-function panel for a patient on CJC-1295, the relevant questions are two separate ones: (1) Is the peptide itself injuring hepatocytes? (2) Is the GH-driven rise in IGF-1 altering hepatic metabolism in ways that affect laboratory values?

The GHRH-GH-IGF-1 Axis and Hepatic Physiology

Growth hormone-releasing hormone (GHRH) is produced by the hypothalamus and reaches the anterior pituitary via the portal circulation. CJC-1295 is a synthetic 29-amino-acid analog of GHRH 1-29, modified with substitutions at positions 2, 8, 15, and 27 to resist dipeptidyl peptidase-IV (DPP-IV) cleavage. The DAC (Drug Affinity Complex) variant adds a lysine-maleimide linker that binds albumin covalently, extending the half-life from roughly 30 minutes to 6-8 days. [1]

Once GH is released, roughly 60-70% of circulating IGF-1 is produced in the liver under GH stimulation. Hepatic IGF-1 then circulates bound to IGF-binding proteins (primarily IGFBP-3 and ALS), and free IGF-1 feeds back to suppress further GH release. [2] This feedback loop is intact with CJC-1295 use, which is one reason the peptide is considered to produce a more physiologic GH pattern than direct GH injection.

Why the Liver Is the Biomarker Organ, Not the Target Organ

Because nearly all clinically measurable IGF-1 is hepatic in origin, serum IGF-1 is effectively a readout of hepatic GH-receptor responsiveness during CJC-1295 therapy. A patient whose IGF-1 rises from 140 ng/mL to 310 ng/mL over 12 weeks is showing adequate hepatic GH-receptor signaling, not hepatic stress.

Conversely, a patient whose IGF-1 fails to rise despite confirmed CJC-1295 absorption may have underlying hepatic insufficiency, since a damaged liver cannot produce adequate IGF-1 even when GH is elevated. [3] This is why baseline IGF-1 below the expected range in an otherwise healthy adult should prompt evaluation of liver synthetic function before initiating any GH secretagogue.

What Teichman et al. (2006) Actually Measured

The Teichman trial is the only peer-reviewed, controlled human pharmacokinetic study of CJC-1295 published in a high-impact journal. Published in the Journal of Clinical Endocrinology and Metabolism, it enrolled 65 healthy adults aged 21-61 years and tested both single and multiple subcutaneous doses. [1]

Study Design and Safety Endpoints

The trial used four single-dose cohorts (30, 60, 120, and 180 mcg/kg) and one multiple-dose cohort (60 mcg/kg once weekly for 6 weeks or once every 2 weeks for 6 weeks). Safety endpoints included standard clinical laboratory panels: complete metabolic panel (CMP), CBC, urinalysis, and lipid profile. Adverse events were systematically collected through a structured diary and follow-up visits.

Teichman et al. Reported that "CJC-1295 was well tolerated at all doses" with no serious adverse events attributed to the compound. The most common adverse effects were transient injection-site reactions and short-duration flushing consistent with vasodilation, both dose-related and self-limiting. [1] No participant met criteria for drug-induced liver injury (DILI) as defined by a greater than 3-fold elevation in ALT or AST above the upper limit of normal (ULN) concurrent with clinical symptoms or bilirubin elevation.

Transaminase Data in Detail

The published paper does not tabulate mean ALT or AST values by cohort, which is a limitation often cited in secondary reviews. What the paper does state is that no laboratory value reached a threshold requiring dose interruption or study discontinuation across all cohorts. At 180 mcg/kg, the highest single dose tested, liver enzymes remained within the protocol-defined safety window.

For clinical context, the 180 mcg/kg dose in a 80 kg adult equals 14,400 mcg (14.4 mg) of peptide. Compounding-pharmacy protocols in the United States typically prescribe 1,000-2,000 mcg (1-2 mg) per injection, placing standard clinical doses well below the highest dose studied. [1]

IGF-1 Trajectory and Its Hepatic Implications

Mean IGF-1 increased 1.5- to 3-fold above baseline in the multiple-dose cohort and remained elevated for 9-11 days after the final injection in the DAC variant. [1] This sustained elevation reflects prolonged hepatic GH-receptor activation. No participant showed signs of IGF-1-mediated hepatomegaly or biochemical evidence of hepatic hypertrophy at the protocol durations studied (up to 6 weeks).

GH-Axis Activation and Liver Enzymes: What the Broader Literature Shows

CJC-1295-specific human liver-safety data beyond Teichman et al. Are sparse. Extrapolation from closely related pharmacology is therefore necessary, and that extrapolation is scientifically defensible given the shared mechanism.

Evidence From GH-Replacement Therapy

Recombinant human GH (rhGH) therapy in adults with GH deficiency produces the same downstream hepatic signal as CJC-1295, namely elevated IGF-1 via GH-receptor stimulation. A Cochrane review of rhGH in adults with GH deficiency (27 RCTs, N=1,415) found no statistically significant increase in ALT or AST versus placebo at standard replacement doses. [4] Mild, transient alkaline phosphatase (ALP) elevations were noted in some cohorts, attributed to increased bone turnover rather than hepatocyte injury.

Supraphysiologic rhGH doses, by contrast, have been linked to insulin resistance and modest ALP elevation through increased bile-acid secretion. The relevance to CJC-1295 is limited because the peptide relies on intact pituitary negative feedback to prevent supraphysiologic GH surges, a regulatory mechanism bypassed by direct GH injection. [2]

NAFLD, IGF-1 Deficiency, and the Hepatoprotective Hypothesis

A counterintuitive body of evidence suggests that low IGF-1 correlates with nonalcoholic fatty liver disease (NAFLD) severity, and that GH-axis deficiency may worsen hepatic steatosis. A 2018 study in Hepatology (N=2,293) found that IGF-1 levels in the lowest quartile were independently associated with a 2.1-fold higher odds of NAFLD on ultrasound (P<0.001). [5]

This does not mean CJC-1295 treats NAFLD. It does suggest that the hepatic consequence of moderately elevated IGF-1 is unlikely to be injurious in patients with normal baseline liver function. Prospective interventional data in NAFLD patients using CJC-1295 specifically do not exist, and that absence of data is not evidence of safety in that population.

Insulin Sensitivity, GH Pulsatility, and Hepatic Glucose Output

One mechanism by which GH can affect liver labs indirectly is through transient insulin resistance. Acute GH peaks suppress hepatic insulin signaling, raising fasting glucose and potentially elevating ALT if the metabolic milieu favors lipid accumulation. [6] CJC-1295's pulsatile, physiologic GH pattern is thought to minimize this effect compared to daily rhGH injection, but no head-to-head comparison in humans has been published.

In practice, prescribers should check fasting glucose and HbA1c alongside liver enzymes, particularly in patients with metabolic syndrome or BMI above 30.

Hepatic IGF-1 Synthesis: The Biochemistry Behind the Labs

The following framework describes the three clinically relevant stages of hepatic involvement during CJC-1295 therapy and the lab tests that correspond to each stage. This schema is not derived from a single published source; it represents a synthesis of GHRH pharmacology, GH-receptor physiology, and standard hepatology practice to give prescribers a structured monitoring approach.

Stage 1: Baseline Assessment (Before First Dose)

Before initiating CJC-1295, the clinician should establish:

• Comprehensive metabolic panel (CMP) including AST, ALT, ALP, total bilirubin, albumin, total protein
• Serum IGF-1 (age- and sex-adjusted reference range)
• Fasting glucose and HbA1c
• Fasting insulin (optional but useful in metabolic syndrome)
• Lipid panel

A baseline ALT above 2 times the ULN warrants hepatology evaluation before prescribing. Uncontrolled diabetes or NAFLD with fibrosis stage F3-F4 represents a relative contraindication given the lack of safety data in those populations.

Stage 2: Early Monitoring (Weeks 4-12)

At approximately 4-6 weeks, the primary signal to track is IGF-1 response. An IGF-1 that rises above the age-adjusted upper limit of normal (typically above 350 ng/mL in adults under 50) is a signal to reduce dose or frequency. ALT and AST at this interval serve as a hepatocyte-integrity check.

The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency specifies maintaining IGF-1 "within the age- and sex-adjusted normal range" and checking IGF-1 at 1-2 months after dose initiation, then every 6 months thereafter. [7] Though written for rhGH, this interval guidance is the most evidence-based framework available for GH-axis peptide monitoring.

Stage 3: Steady-State Monitoring (Every 6 Months)

At steady state, CMP and IGF-1 every 6 months is a reasonable minimum. Patients on concurrent anabolic therapies (testosterone, DHEA, SARMs) may need quarterly labs because multiple anabolic signals can compound hepatic metabolic load. Oral anabolic agents specifically are associated with cholestatic liver injury; injectable CJC-1295 does not share the first-pass hepatic exposure that drives 17-alpha-alkylated hepatotoxicity. [8]

Factors That Modify Liver Risk During CJC-1295 Therapy

Not every patient on CJC-1295 carries the same hepatic risk profile. Several variables shift the probability of abnormal liver labs.

Concurrent Medications and Supplements

Acetaminophen above 2 g/day, high-dose statins, and hepatically metabolized azole antifungals all raise baseline transaminase risk. A patient taking atorvastatin 80 mg plus CJC-1295 whose ALT rises mildly at month 3 presents a diagnostic challenge: the statin is statistically more likely to be the driver, but both should be reviewed. [9]

Bodybuilding supplements containing proprietary blends frequently contain undisclosed hepatotoxic compounds. Patients using CJC-1295 in a performance context should provide a complete supplement inventory at every visit.

Pre-Existing Liver Conditions

Patients with compensated cirrhosis (Child-Pugh A) have reduced hepatic GH-receptor density and blunted IGF-1 responses to exogenous GH stimulation. [3] In practice, this means a cirrhotic patient may fail to show IGF-1 response while still experiencing pituitary GH surges, creating a scenario where GH rises without the expected hepatic counterregulation. These patients should not receive CJC-1295 outside a monitored research setting.

Patients with Gilbert syndrome (benign unconjugated hyperbilirubinemia due to UGT1A1 polymorphism) will show intermittently elevated bilirubin independent of CJC-1295. Clinicians should confirm the Gilbert diagnosis before attributing any bilirubin finding to the peptide.

Age and Sex Effects on Hepatic GH Signaling

GH-receptor expression and post-receptor JAK2-STAT5 signaling efficiency decline with age. Adults over 60 may show blunted IGF-1 responses to the same CJC-1295 dose that raises IGF-1 robustly in a 35-year-old. [2] This blunting does not increase hepatotoxicity risk; it simply means the hepatic effector response is attenuated.

Women produce more total GH pulses per 24 hours than men but have lower portal GH delivery to the liver per pulse, resulting in lower baseline IGF-1 for equivalent body composition. [2] Women on CJC-1295 may need slightly higher doses to achieve equivalent IGF-1 targets, and their baseline IGF-1 reference range must be sex-adjusted for monitoring to be meaningful.

Direct Hepatotoxicity: Mechanism-Based Risk Assessment

CJC-1295 is a peptide, not a small-molecule xenobiotic. Its hepatotoxicity profile differs fundamentally from that of drugs like acetaminophen (direct mitochondrial toxin), amoxicillin-clavulanate (immune-mediated DILI), or 17-alpha-alkylated anabolic steroids (cholestatic injury through bile-salt export pump inhibition).

Peptide ADME and Hepatic Clearance

Peptides are hydrolyzed by circulating and tissue proteases to amino acids and small peptide fragments. CJC-1295 without DAC is cleaved primarily by DPP-IV and neutral endopeptidases in plasma, not by hepatic CYP450 enzymes. The DAC variant, once albumin-bound, is cleared by lysosomal proteolysis after albumin catabolism, a process distributed across multiple tissues including the liver but without producing reactive metabolites that could alkylate hepatic proteins. [1]

This ADME profile means CJC-1295 does not generate the quinone, epoxide, or acyl-glucuronide metabolites that drive most drug-induced liver injury cases in the FDA's DILI database. [10]

Idiosyncratic DILI Risk

Idiosyncratic DILI is inherently unpredictable, occurring at an incidence of roughly 1 in 10,000 to 1 in 100,000 exposed patients for any given drug. No peptide GHRH analog has been reported in LiverTox (the NIH's comprehensive DILI knowledge database) with a confirmed hepatotoxicity rating. [10] That absence reflects both the low intrinsic hepatotoxic potential of peptides and the limited post-marketing surveillance infrastructure for 503A compounded products.

Prescribers should document baseline labs and any subsequent enzyme elevation as a matter of pharmacovigilance, since compounded CJC-1295 lacks the systematic adverse-event reporting that FDA-approved drugs carry.

Clinical Monitoring Protocol: A Practical Summary

The absence of a CJC-1295-specific FDA label means prescribers must build monitoring protocols from first principles. The following is consistent with the Endocrine Society's guidance on GH-axis therapy [7] and standard hepatology practice for drugs with limited DILI data. [9]

Recommended Lab Schedule

| Timepoint | Labs | |---|---| | Baseline | CMP, IGF-1, HbA1c, fasting glucose, fasting lipids | | Week 4-6 | IGF-1, ALT, AST, fasting glucose | | Month 3 | Full CMP, IGF-1, HbA1c, lipids | | Every 6 months (ongoing) | CMP, IGF-1 |

Thresholds for Dose Modification

An ALT or AST elevation above 3 times ULN should prompt immediate dose suspension and repeat testing in 2 weeks. If values normalize off drug and recur with re-challenge, discontinue permanently and refer to hepatology. An IGF-1 persistently above 1.3 times the upper limit of the age-sex-adjusted reference range warrants dose reduction of approximately 25-30% followed by recheck in 6 weeks.

Interpreting ALP Elevations

Isolated ALP elevation in a patient on CJC-1295 is most often bone-derived rather than hepatic in origin, since GH stimulates osteoblast activity. Fractionating ALP into hepatic and bone isoforms (or checking GGT, which is liver-specific) resolves this ambiguity in under 48 hours.